Vemurafenib Withdrawn Phase 1 Trials for BRAFV600 Mutation / Stage IV Melanoma Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01843738Radiation Use During Vemurafenib Treatment